Back to search results

Mycophenolate Mofetil in Systemic Sclerosis With Subclinical Interstitial Lung Disease

Abroad (travel likely)RecruitingPHASE2

Conditions

Systemic Sclerosis With Lung Involvement · Systemic Sclerosis · Interstitial Lung Disease

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Centre hospitalier de l'Université de Montréal (CHUM), Montreal, Quebec, Canada

    Contact: Study coordinator (Unité d'innovation thérapeutique, CHUM) · uit.eligibilite.chum@ssss.gouv.qc.ca · 5148908000
    Contact: Principal Investigator (Sabrina Hoa, MD MSc)

  • Jewish General Hospital - CIUSSS-COMTL, Montreal, Quebec, Canada

    Contact: Study coordinator (Marie Hudson, MD)
    Contact: Principal Investigator (Marie Hudson, MD)

  • Institut Universitaire de Cardiologie et Pneumologie de Québec, Québec, Quebec, Canada

    Contact: Study coordinator (Geneviève Dion, MD) · genevieve.dion.med@ssss.gouv.qc.ca
    Contact: Principal Investigator (Geneviève Dion, MD)
Study leads

  • Sabrina Hoa, MD

    Principal Investigator

    Centre hospitalier de l'Université de Montréal (CHUM)

View source on ClinicalTrials.gov(opens in a new tab)